Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $18.1 million.

  • Mirum Pharmaceuticals' Share-based Compensation rose 52.23% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.6 million, marking a year-over-year increase of 46.17%. This contributed to the annual value of $48.4 million for FY2024, which is 38.32% up from last year.
  • Mirum Pharmaceuticals' Share-based Compensation amounted to $18.1 million in Q3 2025, which was down 1.85% from $18.5 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Share-based Compensation high stood at $18.5 million for Q2 2025, and its period low was $4.8 million during Q2 2021.
  • In the last 3 years, Mirum Pharmaceuticals' Share-based Compensation had a median value of $11.8 million in 2024 and averaged $12.4 million.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Share-based Compensation surged by 116.31% in 2021 and then decreased by 6.84% in 2022.
  • Quarterly analysis of 5 years shows Mirum Pharmaceuticals' Share-based Compensation stood at $5.6 million in 2021, then rose by 23.94% to $6.9 million in 2022, then skyrocketed by 40.95% to $9.7 million in 2023, then surged by 36.33% to $13.3 million in 2024, then spiked by 52.23% to $18.1 million in 2025.
  • Its Share-based Compensation was $18.1 million in Q3 2025, compared to $18.5 million in Q2 2025 and $15.8 million in Q1 2025.